We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01683422
Recruitment Status : Recruiting
First Posted : September 11, 2012
Last Update Posted : October 25, 2017
Information provided by (Responsible Party):

February 17, 2012
September 11, 2012
October 25, 2017
December 2011
December 2022   (Final data collection date for primary outcome measure)
To determine the one-year survival rate [ Time Frame: One year ]
Same as current
Complete list of historical versions of study NCT01683422 on ClinicalTrials.gov Archive Site
To evaluate the frequency of serious adverse events [ Time Frame: Ongoing ]
Same as current
Not Provided
Not Provided
Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer
A Phase II Trial of Gemcitabine and Erlotinib (GE) Plus Proton-chemotherapy (PCT) and Capox for Locally Advanced Pancreatic Cancer (LAPC)
The current trial will provide important data on the recurrence rates and patterns of failure using state of the art target agent, chemotherapy and proton beam technology for patients with Locally Advanced Pancreatic Cancer (LAPC). A median survival of 10 months or greater would be considered evidence of a regimen potentially worthy of further study as a new treatment paradigm in one arm in a future phase III trial.
Not Provided
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Pancreatic Cancer
  • Radiation: Proton, Gemcitabine, Erlotinib, Capecitabine

    Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.

    Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles.

  • Radiation: Proton Radiation
Experimental: Proton Radiation
  • Radiation: Proton, Gemcitabine, Erlotinib, Capecitabine
  • Radiation: Proton Radiation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2024
December 2022   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed unresectable non-metastatic adenocarcinoma of the pancreas
  • AJCC stage I-III with unresectable or borderline unresectable disease as defined by NCCN guidelines
  • Radiological resectability is defined by the following criteria on abdominal imaging:

    1. No evidence of tumor extension to the celiac axis, hepatic artery or superior mesenteric artery.
    2. No evidence of tumor encasement or occlusion of the superior mesenteric vein (SMV) or the SMV/portal vein confluence
    3. No evidence of visceral or peritoneal metastases
  • Borderline and Unresectable cases would be defined as those that do not meet the criteria in section and also show no evidence of distant metastatic or intraperitoneal disease.
  • Eastern Cooperative Oncology Group performance status of ≤ 2
  • Age > 18 years
  • Adequate hematologic reserve, hepatic reserve and renal function
  • WBC > 2,000 cells/mm3
  • ANC > 1,500 cells/mm3
  • Platelets > 100,000 cells/mm3
  • Serum bilirubin ≤ 2.5 mg/dL
  • Serum creatinine ≤ 2 x upper limit of normal (ULN), or creatinine clearance (Ccr) ≥ 30ml/min
  • ALT < 3 times ULN
  • AST < 3 times ULN
  • Albumin > 3.2 g/dl
  • Patient must sign study-specific informed consent
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact: Bernadette Bautista, RN 800-496-4966 or 909-558-4000 ext 88213 bbautista@llu.edu
Contact: Gary Yang, MD Back-up: Sandi Teichman, RN ext 909-558-8231 scteichm@llu.edu
United States
Not Provided
Plan to Share IPD: No
Gary Yang, MD, Loma Linda University
Loma Linda University
Not Provided
Principal Investigator: Gary Yang, MD gyang@llu.edu
Loma Linda University
October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP